{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T22:28:39Z","timestamp":1788560919284,"version":"build-2803163510"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.schres.2024.08.001","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T06:59:12Z","timestamp":1725951552000},"page":"57-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Efficacy of KarXT on negative symptoms in acute schizophrenia: A post hoc analysis of pooled data from 3 trials"],"prefix":"10.1016","volume":"274","author":[{"given":"William P.","family":"Horan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Targum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Claxton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inder","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha E.","family":"Yohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Marder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen K.","family":"Brannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2024.08.001_bb0005","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/hbm.23439","article-title":"Fronto-temporal connectivity predicts cognitive empathy deficits and experiential negative symptoms in schizophrenia","volume":"38","author":"Abram","year":"2017","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.schres.2024.08.001_bb0010","series-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM-5","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.schres.2024.08.001_bb0015","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1017\/S1461145710001549","article-title":"The M(1)\/M(4) preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia","volume":"14","author":"Barak","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2024.08.001_bb0020","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.08.001_bb0025","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/schbul\/sbj013","article-title":"The structure of negative symptoms within schizophrenia: implications for assessment","volume":"32","author":"Blanchard","year":"2006","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2024.08.001_bb0030","series-title":"Toward the Next Generation of Negative Symptom Assessments: The Collaboration to Advance Negative Symptom Assessment in Schizophrenia. Schizophrenia Bulletin","first-page":"37","author":"Blanchard","year":"2011"},{"key":"10.1016\/j.schres.2024.08.001_bb0035","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4088\/JCP.08m04250yel","article-title":"Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study","volume":"71","author":"Bobes","year":"2010","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.schres.2024.08.001_bb0040","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","article-title":"Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease","volume":"54","author":"Bodick","year":"1997","journal-title":"Arch. Neurol."},{"issue":"Suppl. 4","key":"10.1016\/j.schres.2024.08.001_bb0045","article-title":"The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease","volume":"11","author":"Bodick","year":"1997","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.schres.2024.08.001_bb0050","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa2017015","article-title":"Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia","volume":"384","author":"Brannan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2024.08.001_bb0055","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00213-023-06362-2","article-title":"Evidence of trospium\u2019s ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results","volume":"240","author":"Breier","year":"2023","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2024.08.001_bb0060","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.euroneuro.2020.03.010","article-title":"Persistent negative symptoms in recent-onset psychosis: relationship to treatment response and psychosocial functioning","volume":"34","author":"Bucci","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2024.08.001_bb0065","doi-asserted-by":"crossref","DOI":"10.1017\/S1092852914000601","article-title":"Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia","volume":"19","author":"Carbon","year":"2014","journal-title":"CNS Spectr."},{"key":"10.1016\/j.schres.2024.08.001_bb0070","doi-asserted-by":"crossref","DOI":"10.5402\/2012\/595141","article-title":"Comparative evaluation of forced swim test and tail suspension test as models of negative symptom of schizophrenia in rodents","volume":"2012","author":"Chatterjee","year":"2012","journal-title":"ISRN Psychiatry"},{"key":"10.1016\/j.schres.2024.08.001_bb0075","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0166-4328(03)00221-3","article-title":"The relation between latent inhibition and symptom-types in young schizophrenics","volume":"149","author":"Cohen","year":"2004","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.schres.2024.08.001_bb0080","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41537-022-00320-1","article-title":"Safety and tolerability of KarXT (xanomeline-trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia","volume":"8","author":"Correll","year":"2022","journal-title":"Schizophrenia (Heidelb)"},{"key":"10.1016\/j.schres.2024.08.001_bb0085","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.schres.2018.08.020","article-title":"Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: a post hoc analysis of pooled data","volume":"204","author":"Earley","year":"2019","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.08.001_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbr.2008.08.023","article-title":"Enhancement of latent inhibition in patients with chronic schizophrenia","volume":"197","author":"Gal","year":"2009","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.schres.2024.08.001_bb0095","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S2215-0366(18)30050-6","article-title":"Negative symptoms of schizophrenia: new developments and unanswered research questions","volume":"5","author":"Galderisi","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.schres.2024.08.001_bb0100","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/npp.2015.189","article-title":"Potentiation of M1 muscarinic receptor reverses plasticity deficits and negative and cognitive symptoms in a schizophrenia mouse model","volume":"41","author":"Ghoshal","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2024.08.001_bb0105","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1037\/a0037098","article-title":"Randomized clinical trial of cognitive behavioral social skills training for schizophrenia: improvement in functioning and experiential negative symptoms","volume":"82","author":"Granholm","year":"2014","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.schres.2024.08.001_bb0110","doi-asserted-by":"crossref","DOI":"10.2196\/24406","article-title":"Mobile-assisted cognitive behavioral therapy for negative symptoms: open single-arm trial with schizophrenia patients","volume":"7","author":"Granholm","year":"2020","journal-title":"JMIR Ment. Health"},{"key":"10.1016\/j.schres.2024.08.001_bb0115","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/schbul\/sbab126","article-title":"Integrated cognitive-behavioral social skills training and compensatory cognitive training for negative symptoms of psychosis: effects in a pilot randomized controlled trial","volume":"48","author":"Granholm","year":"2022","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2024.08.001_bb0120","series-title":"ECDEU Assessment Manual for Psychopharmacology. Revised","author":"Guy","year":"1976"},{"key":"10.1016\/j.schres.2024.08.001_bb0125","first-page":"18","article-title":"Using the Positive and Negative Syndrome Scale (PANSS) to define different domains of negative symptoms: prediction of everyday functioning by impairments in emotional expression and emotional experience","volume":"14","author":"Harvey","year":"2017","journal-title":"Clin. Neurosci."},{"key":"10.1016\/j.schres.2024.08.001_bb0130","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.schres.2018.11.005","article-title":"Predictors of social functioning in patients with higher and lower levels of reduced emotional experience: social cognition, social competence, and symptom severity","volume":"206","author":"Harvey","year":"2019","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.08.001_bb0135","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.psychres.2019.01.045","article-title":"Virtual reality assessment of functional capacity in people with schizophrenia: associations with reduced emotional experience and prediction of functional outcomes","volume":"277","author":"Harvey","year":"2019","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2024.08.001_bb0140","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.schres.2019.08.029","article-title":"Effects of Roluperidone (MIN-101) on two dimensions of the negative symptoms Factor Score: reduced emotional experience and reduced emotional expression","volume":"215","author":"Harvey","year":"2020","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.08.001_bb0145","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1176\/ajp.151.10.1409","article-title":"One hundred years of schizophrenia: a meta-analysis of the outcome literature","volume":"151","author":"Hegarty","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.08.001_bb0150","first-page":"54","article-title":"Understanding antipsychotic drug treatment effects: a novel method to reduce Pseudospecificity of the Positive and Negative Syndrome Scale (PANSS) factors","volume":"14","author":"Hopkins","year":"2017","journal-title":"Innov. Clin. Neurosci."},{"key":"10.1016\/j.schres.2024.08.001_bb0155","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/schbul\/sbj009","article-title":"Anhedonia in schizophrenia: a review of assessment strategies","volume":"32","author":"Horan","year":"2006","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2024.08.001_bb0160","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/7854_2022_382","article-title":"An update on treatment of cognitive impairment associated with schizophrenia","volume":"63","author":"Horan","year":"2023","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.schres.2024.08.001_bb0165","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.2174\/138161209788957528","article-title":"Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging","volume":"15","author":"Howes","year":"2009","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.schres.2024.08.001_bb0175","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","article-title":"Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial","volume":"403","author":"Kaul","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2024.08.001_bb0180","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2024.0785","article-title":"Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial","author":"Kaul","year":"2024","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.schres.2024.08.001_bb0185","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2024.08.001_bb0190","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1017\/S095457941500019X","article-title":"Dysplasticity, metaplasticity, and schizophrenia: implications for risk, illness, and novel interventions","volume":"27","author":"Keshavan","year":"2015","journal-title":"Dev. Psychopathol."},{"key":"10.1016\/j.schres.2024.08.001_bb0195","first-page":"30","article-title":"Negative symptom dimensions of the positive and negative syndrome scale across geographical regions: implications for social, linguistic, and cultural consistency","volume":"14","author":"Khan","year":"2017","journal-title":"Innov. Clin. Neurosci."},{"key":"10.1016\/j.schres.2024.08.001_bb0200","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/schbul\/sbj053","article-title":"The NIMH-MATRICS consensus statement on negative symptoms","volume":"32","author":"Kirkpatrick","year":"2006","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2024.08.001_bb0205","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.schres.2017.11.031","article-title":"The brief negative symptom scale (BNSS): sensitivity to treatment effects","volume":"197","author":"Kirkpatrick","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.08.001_bb0210","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1476-5381.2010.01080.x","article-title":"Involvement of decreased muscarinic receptor function in prepulse inhibition deficits in mice reared in social isolation","volume":"162","author":"Koda","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.schres.2024.08.001_bb0215","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1756-6606-5-10","article-title":"M4 muscarinic receptor knockout mice display abnormal social behavior and decreased prepulse inhibition","volume":"5","author":"Koshimizu","year":"2012","journal-title":"Mol. Brain"},{"key":"10.1016\/j.schres.2024.08.001_bb0220","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.biopsych.2005.09.014","article-title":"Size of treatment effects and their importance to clinical research and practice","volume":"59","author":"Kraemer","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2024.08.001_bb0225","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.euroneuro.2018.09.007","article-title":"Antipsychotic drugs for elderly patients with schizophrenia: a systematic review and meta-analysis","volume":"28","author":"Krause","year":"2018","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2024.08.001_bb0230","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1176\/appi.ajp.2012.12010109","article-title":"The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation","volume":"170","author":"Kring","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.08.001_bb0235","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/sj.npp.1301563","article-title":"Neuroplasticity of neocortical circuits in schizophrenia","volume":"33","author":"Lewis","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2024.08.001_bb0240","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.2174\/1568026616666160608084834","article-title":"Dopamine targeting drugs for the treatment of schizophrenia: past, present and future","volume":"16","author":"Li","year":"2016","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.schres.2024.08.001_bb0245","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.schres.2023.07.010","article-title":"Negative symptoms in schizophrenia: newly emerging measurements, pathways, and treatments","volume":"258","author":"Marder","year":"2023","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.08.001_bb0250","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4088\/JCP.v58n1205","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials","volume":"58","author":"Marder","year":"1997","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.schres.2024.08.001_bb0255","first-page":"740","article-title":"Cognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trials","volume":"11","author":"McArthur","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.schres.2024.08.001_bb0260","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.schres.2003.11.008","article-title":"The heterogeneity of schizophrenia in disease states","volume":"71","author":"Mohr","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.08.001_bb0265","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/s41386-020-00916-0","article-title":"The M1\/M4 preferring muscarinic agonist xanomeline modulates functional connectivity and NMDAR antagonist-induced changes in the mouse brain","volume":"46","author":"Montani","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2024.08.001_bb0270","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(17)30060-0","article-title":"Cariprazine vs risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial","volume":"389","author":"Nemeth","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2024.08.001_bb0275","first-page":"638","article-title":"Schizophrenia: overview and treatment options","volume":"39","author":"Patel","year":"2014","journal-title":"P T."},{"key":"10.1016\/j.schres.2024.08.001_bb0280","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/appi.ajp.21101083","article-title":"Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia","volume":"179","author":"Paul","year":"2022","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.08.001_bb0285","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1176\/appi.ajp.20220243","article-title":"A novel psychosocial intervention for motivational negative symptoms in schizophrenia: combined motivational interviewing and CBT","volume":"180","author":"Reddy","year":"2023","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.08.001_bb0290","doi-asserted-by":"crossref","DOI":"10.32872\/cpe.v2i3.2899","article-title":"Efficacy of psychological treatments for patients with schizophrenia and relevant negative symptoms: a Meta-analysis","volume":"2","author":"Riehle","year":"2020","journal-title":"Clin. Psychol. Eur."},{"key":"10.1016\/j.schres.2024.08.001_bb0295","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1192\/bjp.2022.203","article-title":"Negative symptoms in children and adolescents with early-onset psychosis and at clinical high-risk for psychosis: systematic review and meta-analysis","volume":"223","author":"Salazar de Pablo","year":"2023","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.08.001_bb0300","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0920-9964(99)00138-3","article-title":"Xanomeline, an M(1)\/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice","volume":"42","author":"Shannon","year":"2000","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.08.001_bb0305","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia","volume":"165","author":"Shekhar","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.08.001_bb0310","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12888-014-0225-8","article-title":"Impact of negative symptoms on healthcare resource utilization and associated costs in adult outpatients with schizophrenia: a population-based study","volume":"14","author":"Sicras-Mainar","year":"2014","journal-title":"BMC Psychiatr."},{"key":"10.1016\/j.schres.2024.08.001_bb0315","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"10.1016\/j.schres.2024.08.001_bb0320","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0022-3565(24)29291-0","article-title":"The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat","volume":"299","author":"Stanhope","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.schres.2024.08.001_bb0325","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jpsychires.2018.06.018","article-title":"Which levels of cognitive impairments and negative symptoms are related to functional deficits in schizophrenia?","volume":"104","author":"Strassnig","year":"2018","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2024.08.001_bb0330","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jpsychires.2013.01.015","article-title":"Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome","volume":"47","author":"Strauss","year":"2013","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2024.08.001_bb0335","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/wps.20567","article-title":"Management of common adverse effects of antipsychotic medications","volume":"17","author":"Stroup","year":"2018","journal-title":"World Psychiatry"},{"key":"10.1016\/j.schres.2024.08.001_bb0340","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00213-013-3256-9","article-title":"Acute and chronic effects of the M1\/M4-preferring muscarinic agonist xanomeline on cocaine vs food choice in rats","volume":"231","author":"Thomsen","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2024.08.001_bb0345","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/00002093-199812000-00010","article-title":"Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB)","volume":"12","author":"Veroff","year":"1998","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.schres.2024.08.001_bb0350","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejphar.2008.12.020","article-title":"Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice","volume":"603","author":"Woolley","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.schres.2024.08.001_bb0355","series-title":"H. S: NS-136, a Selective Muscarinic Receptor Positive Allosteric Modulator (PAM) for the Treatment of Schizophrenia. In Society for Neuroscience. Washington, D.C","author":"Wu","year":"2023"},{"key":"10.1016\/j.schres.2024.08.001_bb0360","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.neuropharm.2017.09.012","article-title":"Positive allosteric modulation of M(1) and M(4) muscarinic receptors as potential therapeutic treatments for schizophrenia","volume":"136","author":"Yohn","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.schres.2024.08.001_bb0365","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.1016\/j.biopsych.2019.03.442","article-title":"Differences in nucleus accumbens dopamine release via muscarinic acetylcholine receptor subtypes: implications for manifestation of negative symptoms. In society for","author":"Yohn","year":"2019","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2024.08.001_bb0370","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.tips.2022.09.006","article-title":"Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic","volume":"43","author":"Yohn","year":"2022","journal-title":"Trends Pharmacol. Sci."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996424003724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996424003724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T04:40:17Z","timestamp":1762317617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996424003724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":73,"alternative-id":["S0920996424003724"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2024.08.001","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of KarXT on negative symptoms in acute schizophrenia: A post hoc analysis of pooled data from 3 trials","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2024.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}